Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Financing › Details

GNA Biosolutions–btov Partners: investment, 201908 financing round Series C totalling $13.5m incl existing investor btov Partners

 

Period Period 2019-08-05
Organisations Money taker GNA Biosolutions GmbH
  Money source btov Partners (b-to-v Partners AG)
Products Product molecular diagnostics
  Product 2 venture capital
Index term Index term GNA Biosolutions–SEVERAL: investment, 201908 financing round Series C $13.5m from new + existing EU + US investors
     

GNA Biosolutions GmbH. (8/5/19). "Press Release: GNA Biosolutions Closes $13.5M Series C Financing Round Backed by a US/EU consortium". Munich.

Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology


GNA Biosolutions GmbH, a molecular diagnostics company based in Germany, announced today that it has completed a $13.5M round of financing.

The Series C financing round was joined by new investors including GreyBird Ventures, Occident, and Wachstumsfonds Bayern, and existing investors SHS Gesellschaft für Beteiligungsmanagement, Robert Bosch Venture Capital, UVC Partners, Mey Capital Matrix, KfW, and btov Partners. Proceeds from the financing will be used to advance development and secure IVD-CE marking of GNA’s first Point of Care molecular diagnostic platform.

GNA Biosolutions has pioneered a next generation nucleic acid amplification technology (Pulse Controlled Amplification – PCA) in the field of molecular diagnostics. The company’s PCA platform amplifies nucleic acids captured directly from complex samples such as whole blood, sputum, and nasal swabs within minutes, without the need for additional sample preparation and with minimal hands-on time.

“We are excited to work with the GNA team and look forward to supporting this stage of the company. Rapid molecular diagnostics are key to patient care across an increasingly broad range of therapeutic areas, and particularly infectious diseases. We believe PCA technology will resolve many limitations of existing molecular diagnostics, enabling fast therapeutic decisions that improve patient care,” said Tom Miller, partner at GreyBird Ventures, lead investor for the round. Mr. Miller, a global healthcare industry leader and an experienced and visionary CEO, will serve as Chairman of GNA’s Board effective immediately.

“We are very appreciative of the enthusiastic response from our new investors and the continued support of our existing consortium. This Series C funding will help us execute our regulatory strategy and bring PCA to the clinic,” said Federico Buersgens, co-founder and Managing Director of GNA Biosolutions. GNA plans to launch its POC platform first in the EU, followed by the US. “We believe having this unique combination of European and US investors on board gives GNA an edge – we have assembled a great consortium which will provide us not only with a tremendous depth of experience but also visibility and access to decision makers across our key launch markets” said Mr. Buersgens.

GNA’s breakthrough technology allows the development of cost effective and simple-to-perform molecular diagnostic tests. The company’s prototype platform has been utilized in more than 30 assays in-house and with partners, including assays for Hospital Acquired Infections and Tuberculosis, and biothreats such as Ebola and Plague.

GNA is the winner of AACC’s 2018 Disruptive Technology Award and a Showcase Company in the 2019 MedTech Innovator Competition.


About GNA Biosolutions

GNA Biosolutions is a private molecular diagnostics company located in Germany. Our proprietary PCA technology offers a novel, ultrafast, and cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. PCA assays are being developed for a number of therapeutic areas, including infectious diseases and biothreats.

The company’s first Point of Care product will be utilized for the diagnosis of antibiotic resistant Hospital Acquired Infections (HAIs) and Tuberculosis (TB). PCA technology has not been cleared or approved by European of U.S. regulatory agencies and is currently for research use only.

For more information, please visit www.gna-bio.com


Contacts

GNA Biosolutions GmbH
Anastasia Liapis – Head of Strategic Marketing & Partnerships
communications@gna-bio.com

   
Record changed: 2019-08-08

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for GNA Biosolutions GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top